Expanding Innovative Portfolio Could Boost Sun Pharma Stock Gains

Sun Pharma’s Innovative Strategy Poised to Drive Stock Performance

With a series of strategic moves in its innovative portfolio, Sun Pharma is positioning itself for potential stock gains amidst a challenging market landscape.

Positive Catalysts on the Horizon

Sun Pharma’s stock has faced pressure over the past six months, underperforming its peers. However, several catalysts are emerging that could reverse this trend. The recent in-licensing agreement with LIB Therapeutics to commercialize Lerodalcibep, a cholesterol-lowering medication, is a significant step forward. This drug belongs to the PCSK9 class, which is gaining traction in the market, and the deal opens access to a projected $3.7 billion market, growing at an annual rate of 38%.

The global PCSK9 market is expected to reach approximately $7 billion by 2026, indicating a robust growth opportunity for Sun Pharma. The company will handle regulatory approvals in territories where they are pending, further solidifying its commitment to expanding its innovative portfolio.

Strengthening the Innovative Portfolio

According to 360 ONE Capital Research, this licensing deal builds on Sun Pharma’s history of enhancing its innovative portfolio through strategic in-licensing and acquisitions. The company reported a 16.8% growth in innovative medicines revenue, reaching $1.42 billion in FY26. Notably, the plaque psoriasis drug Ilumya, which generated $796 million in sales, continues to show strong year-on-year growth.

Moreover, upcoming catalysts such as potential USFDA approval for Ilumya in treating psoriatic arthritis and the ongoing ramp-up of its hair loss treatment, Leqselvi, are expected to contribute positively to the company’s growth trajectory.

Tariff Deal and Broader Market Implications

Another significant development is the recent tariff deal with the US, which extends the most favored nation drug pricing to state Medicaid programs while excluding Medicare. This arrangement is crucial as it protects the majority of Sun Pharma’s innovative medicine sales. The tariff protection for its US branded portfolio is set to last until January 20, 2029, providing a stable revenue outlook amidst potential pricing pressures.

While lower Medicaid pricing may impact earnings, the exclusion of Medicare and the tariff reprieve are seen as marginally positive for Sun Pharma’s overall financial health. Analysts from Kotak Research have rated the stock with an ‘add’ rating and a target price of ₹2,150.

Future Growth Prospects

Geojit Research also expresses optimism regarding Sun Pharma’s future, highlighting the recent approval of semaglutide in multiple markets and the steady performance of flagship brands like Ilumya. The proposed acquisition of Organon, expected to broaden its therapeutic presence in women’s health and biosimilars, is anticipated to enhance Sun Pharma’s global reach and market presence.

With a revised target price of ₹2,070, Geojit Research maintains a ‘buy’ rating on the stock, reflecting confidence in Sun Pharma’s innovation-led growth strategy.

Key Highlights

• Sun Pharma’s stock is currently priced at ₹1,860, trading at 27 times FY28 earnings estimates.
• The in-licensing deal for Lerodalcibep opens a $3.7 billion market opportunity.
• The global PCSK9 market is projected to reach $7 billion by 2026.
• Analysts have set target prices ranging from ₹2,070 to ₹2,250 for Sun Pharma stock.
• The tariff deal with the US protects Sun Pharma’s branded portfolio until January 2029.

Investor Note: The strategic expansion of Sun Pharma’s innovative portfolio, coupled with favorable market conditions and regulatory developments, positions the company for potential stock gains, making it an attractive option for investors looking for growth in the pharmaceutical sector.